Ligand (LGND) Director Jason Haas Exercises Options, Sells Shares

What Happened
Jason Haas, a director of Ligand Pharmaceuticals (LGND), exercised options for 6,138 shares on August 12, 2026, at an exercise price of $51.56 per share (total cost reported $316,475). On the same day he sold 7,138 shares in the open market for a weighted-average price of $292.81, generating proceeds of about $2,090,062. The filing also reports a conversion/derivative entry for 6,138 shares at $0, which reflects the conversion step associated with the option exercise.

Key Details

• Transaction date: 2026-08-12; Form 4 filed 2026-08-14 (timely).
• Option exercise: 6,138 shares at $51.56 each; total exercise cost $316,475.
• Open-market sale: 7,138 shares; weighted-average sale price $292.81; total proceeds ≈ $2,090,062. (Sale prices ranged $292.50–$292.855 — see footnote F1.)
• Derivative reporting: 6,138 shares reported as converted/ disposed at $0 (see filing) — reflects the option conversion step.
• Footnote F2: the option was originally granted June 29, 2022 (5,907-share grant adjusted after corporate separation) and became exercisable per its original vesting schedule, later adjusted.
• Shares owned after the transactions: not specified in the provided filing.

Context

• This filing shows an option exercise paired with same-day share sales. That pattern can reflect an executive exercising vested options and selling shares (often to cover exercise costs, taxes, or to diversify), but the filing does not state the insider’s motive or whether the sales were part of a prearranged plan.
• For retail investors, purchases are typically interpreted as a stronger bullish signal than routine exercises followed by sales; this filing documents both an exercise and a substantial sale.